| Literature DB >> 30056975 |
Frédéric Castinetti1, Frédéric Albarel2, Françoise Archambeaud3, Jérome Bertherat4, Benjamin Bouillet5, Perrine Buffier6, Claire Briet7, Bertrand Cariou8, Philippe Caron9, Olivier Chabre10, Philippe Chanson11, Christine Cortet12, Christine Do Cao12, Delphine Drui8, Magali Haissaguerre13, Ségolène Hescot14, Frédéric Illouz15, Emmanuelle Kuhn11, Najiba Lahlou16, Emilie Merlen12, Véronique Raverot17, Sarra Smati8, Bruno Verges5, Françoise Borson-Chazot18.
Abstract
The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.Entities:
Keywords: Adrenal failure; Diabetes; Dyslipidemia; Dysthyroidism; Hypophysitis; Immunotherapy; MTOR inhibitors; Tyrosine kinase inhibitors
Mesh：
Substances：
Year: 2018 PMID： 30056975 DOI： 10.1016/j.ando.2018.07.005
Source DB: PubMed Journal: Ann Endocrinol (Paris) ISSN： 0003-4266 Impact factor: 2.478